Vimarsana
Biggest News Aggregation in the World

Page 31 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Vimarsana News

BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies

BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs

Pre-market Movers: VALN, GROV, GTIM, BGNE, FEDU. - Vimarsana News

Pre-market Movers: VALN, GROV, GTIM, BGNE, FEDU.

OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.00 A.M. ET).In the GreenValneva SE (VALN) is up over 83% at $25.21 Grove Collaborative

BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab - Vimarsana News

BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 BeiGene

BeiGene, Ltd. (NASDAQ:BGNE) CFO Julia Aijun Wang Sells 161 Shares - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) CFO Julia Aijun Wang Sells 161 Shares

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) CFO Julia Aijun Wang sold 161 shares of BeiGene stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $136.64, for a total value of $21,999.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is […]

BeiGene cancer drug receives further international approval - Vimarsana News

BeiGene cancer drug receives further international approval

Chinese biotech enterprise BeiGene announced on Monday that its cancer treatment Brukinsa (zanubrutinib) has been approved by authorities in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.This development means the drug has received more than 20 approvals covering 50 countries and regions, including the United States, China, the European Union, Great Britain, Canada, and Australia. Currently, more than 40 additional regulatory submissions are in review around the world. BeiGene said it is working with NewBrid...